Menu
GWAS Study

Genetic Contributors of Efficacy and Adverse Metabolic Effects of Chlorthalidone in African Americans from the Genetics of Hypertension Associated Treatments (GenHAT) Study.

Armstrong ND, Srinivasasainagendra V, Chekka LMS et al.

35886043 PubMed ID
GWAS Study Type
4552 Participants
Scroll to explore
Chapter I

Publication Details

Comprehensive information about this research publication

Authors

AN
Armstrong ND
SV
Srinivasasainagendra V
CL
Chekka LMS
NN
Nguyen NHK
NN
Nahid NA
JA
Jones AC
TR
Tanner RM
HB
Hidalgo BA
LN
Limdi NA
CS
Claas SA
GY
Gong Y
MC
McDonough CW
CR
Cooper-DeHoff RM
JJ
Johnson JA
TH
Tiwari HK
AD
Arnett DK
IM
Irvin MR
Chapter II

Abstract

Summary of the research findings

Hypertension is a leading risk factor for cardiovascular disease mortality. African Americans (AAs) have the highest prevalence of hypertension in the United States, and to alleviate the burden of hypertension in this population, better control of blood pressure (BP) is needed. Previous studies have shown considerable interpersonal differences in BP response to antihypertensive treatment, suggesting a genetic component. Utilizing data from 4297 AA participants randomized to chlorthalidone from the Genetics of Hypertension Associated Treatments (GenHAT) study, we aimed to identify variants associated with the efficacy of chlorthalidone. An additional aim was to find variants that contributed to changes in fasting glucose (FG) in these individuals. We performed genome-wide association analyses on the change of systolic and diastolic BP (SBP and DBP) over six months and FG levels over 24 months of treatment. We sought replication in the International Consortia of Pharmacogenomics Studies. We identified eight variants statistically associated with BP response and nine variants associated with FG response. One suggestive LINC02211-CDH9 intergenic variant was marginally replicated with the same direction of effect. Given the impact of hypertension in AAs, this study implies that understanding the genetic background for BP control and glucose changes during chlorthalidone treatment may help prevent adverse cardiovascular events in this population.

3,982 African American individuals

Chapter III

Study Statistics

Key metrics and study information

4552
Total Participants
GWAS
Study Type
Yes
Replicated
570 African American individuals
Replication Participants
African American or Afro-Caribbean
Ancestry
U.S.
Recruitment Country
Chapter IV

Analysis

Comprehensive review of health and genetic findings

Important Disclaimer: This review has been performed semi-automatically and is provided for informational purposes only. While we strive for accuracy, this analysis may contain errors, omissions, or misinterpretations of the original research. DNA Genics disclaims all liability for any inaccuracies, errors, or consequences arising from the use of this information. Users should independently verify all information and consult original research publications before making any decisions based on this content. This analysis is not intended as a substitute for professional scientific review or medical advice.

Analysis In Progress

Our analysis of this publication is currently being prepared. Please check back soon for comprehensive insights into the health and genetic findings discussed in this research.